There are roughly 2,500 public medical facilities in Ukraine that have previously run international clinical trials, and it was an average of 500 clinical trials were ongoing in Ukraine each year, before 24 Feb 2022.
In early April’ 2022, ClinicalTrials.gov listed more than 400 active trials with sites in Ukraine – now hundreds of clinical trials have been halted.
But why to wait till the end of the war to explore again Ukrainian potential in clinical research?
Despite of all challenges, Ukrainian investigators, the medical care system and Ministry of Health demonstrates endurance and ingenuity during these hard times.
It’s a good time to consider Ukraine again as a valuable location for new clinical trials again! Just a few arguments why:
- A great advantage for clinical research in Ukraine is the easy access to a broad group of patients who have not yet been treated with modern therapies, due to economical constraints.
- Therefore, large groups of treatment-naive patients are available for all major therapeutic areas.
- Ukrainian trial sites typically enroll participants 3-6 times faster compared to higher-income countries.
- Patients are highly motivated and willing to participate in clinical trials.
- Recent regulation update allows CA approval in a max of 50-60 calendar days.
- Investigators are ICH GCP experienced, well educated, motivated and deliver high quality data.
- They now benefit from the lack of competition during the war.
Gaea’ core clinical team is experienced Ukrainians, partially based in Estonia, and partially still in Ukraine. We’re ready to conduct a rigorous risk assessment for Sponsors willing to involve Ukraine in their studies, and eager to re-start Ukraine in clinical trials.
Read more about how Ukraine seeks to resume its role in cancer clinical trials here: https://www.nature.com/articles/d41586-023-02606-5
Слава Україні!
